Style | Citing Format |
---|---|
MLA | Safari Z, et al.. "The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers." Chemical Biology and Drug Design, vol. 101, no. 5, 2023, pp. 1204-1215. |
APA | Safari Z, Firouzi A, Rezaeikalantari N, Mohammadi S, Ranjbar N, Shahpori H, Khaleghi P, Bagherianlemraski M, Zandi S, Rafieyan S (2023). The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers. Chemical Biology and Drug Design, 101(5), 1204-1215. |
Chicago | Safari Z, Firouzi A, Rezaeikalantari N, Mohammadi S, Ranjbar N, Shahpori H, Khaleghi P, Bagherianlemraski M, Zandi S, Rafieyan S. "The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers." Chemical Biology and Drug Design 101, no. 5 (2023): 1204-1215. |
Harvard | Safari Z et al. (2023) 'The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers', Chemical Biology and Drug Design, 101(5), pp. 1204-1215. |
Vancouver | Safari Z, Firouzi A, Rezaeikalantari N, Mohammadi S, Ranjbar N, Shahpori H, et al.. The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers. Chemical Biology and Drug Design. 2023;101(5):1204-1215. |
BibTex | @article{ author = {Safari Z and Firouzi A and Rezaeikalantari N and Mohammadi S and Ranjbar N and Shahpori H and Khaleghi P and Bagherianlemraski M and Zandi S and Rafieyan S}, title = {The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers}, journal = {Chemical Biology and Drug Design}, volume = {101}, number = {5}, pages = {1204-1215}, year = {2023} } |
RIS | TY - JOUR AU - Safari Z AU - Firouzi A AU - Rezaeikalantari N AU - Mohammadi S AU - Ranjbar N AU - Shahpori H AU - Khaleghi P AU - Bagherianlemraski M AU - Zandi S AU - Rafieyan S TI - The Salivary Exosomal Microrna As a Potential Biomarker in Patients With Periodontitis and Oral Cancers JO - Chemical Biology and Drug Design VL - 101 IS - 5 SP - 1204 EP - 1215 PY - 2023 ER - |